Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin

G. Derosa, A. D'Angelo, P. D. Ragonesi, L. Ciccarelli, M. N. Piccinni, F. Pricolo, S. A T Salvadeo, L. Montagna, A. Gravina, I. Ferrari, S. Paniga, A. F G Cicero

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Metformin is considered the gold standard for type 2 diabetes treatment as monotherapy and in combination with sulphonylureas and insulin, whereas the combination of metformin with thiazolidinediones is relatively less studied. The aim of the present study was to assess the differential effect on glycaemic metabolism and lipid variables of the combination of metformin plus pioglitazone or metformin plus rosiglitazone in diabetic patients with metabolic syndrome. Methods: All patients began metformin and were randomized to receive pioglitazone or rosiglitazone for 12 months. We assessed body mass index, glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, postprandial plasma insulin, homeostasis model assessment index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B. Results: Significant decreases in glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, and postprandial plasma insulin were seen after 9 and 12 months in both groups. Homeostasis model assessment index improved at 12 months in both groups. Significant total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B improvement was observed in pioglitazone group after 12 months, but not in the rosiglitazone group. These variations were significant between groups. Conclusion: The combination of metformin plus thiazolidinediones was able to improve glycaemic control compared with previous therapy. Pioglitazone was associated with a significant improvement in lipid and lipoprotein variables.

Original languageEnglish
Pages (from-to)79-86
Number of pages8
JournalInternal Medicine Journal
Volume37
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

rosiglitazone
pioglitazone
Metformin
Insulin
Fasting
Glucose
Thiazolidinediones
Apolipoprotein A-I
Glycosylated Hemoglobin A
Apolipoproteins B
LDL Cholesterol
HDL Cholesterol
Triglycerides
Homeostasis
Cholesterol
Lipid Metabolism
Type 2 Diabetes Mellitus

Keywords

  • Lipid
  • Metabolic syndrome
  • Thiazolidinedione
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. / Derosa, G.; D'Angelo, A.; Ragonesi, P. D.; Ciccarelli, L.; Piccinni, M. N.; Pricolo, F.; Salvadeo, S. A T; Montagna, L.; Gravina, A.; Ferrari, I.; Paniga, S.; Cicero, A. F G.

In: Internal Medicine Journal, Vol. 37, No. 2, 02.2007, p. 79-86.

Research output: Contribution to journalArticle

Derosa, G. ; D'Angelo, A. ; Ragonesi, P. D. ; Ciccarelli, L. ; Piccinni, M. N. ; Pricolo, F. ; Salvadeo, S. A T ; Montagna, L. ; Gravina, A. ; Ferrari, I. ; Paniga, S. ; Cicero, A. F G. / Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. In: Internal Medicine Journal. 2007 ; Vol. 37, No. 2. pp. 79-86.
@article{1bd907d833c64673a7dde7e605e39bbd,
title = "Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin",
abstract = "Background: Metformin is considered the gold standard for type 2 diabetes treatment as monotherapy and in combination with sulphonylureas and insulin, whereas the combination of metformin with thiazolidinediones is relatively less studied. The aim of the present study was to assess the differential effect on glycaemic metabolism and lipid variables of the combination of metformin plus pioglitazone or metformin plus rosiglitazone in diabetic patients with metabolic syndrome. Methods: All patients began metformin and were randomized to receive pioglitazone or rosiglitazone for 12 months. We assessed body mass index, glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, postprandial plasma insulin, homeostasis model assessment index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B. Results: Significant decreases in glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, and postprandial plasma insulin were seen after 9 and 12 months in both groups. Homeostasis model assessment index improved at 12 months in both groups. Significant total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B improvement was observed in pioglitazone group after 12 months, but not in the rosiglitazone group. These variations were significant between groups. Conclusion: The combination of metformin plus thiazolidinediones was able to improve glycaemic control compared with previous therapy. Pioglitazone was associated with a significant improvement in lipid and lipoprotein variables.",
keywords = "Lipid, Metabolic syndrome, Thiazolidinedione, Type 2 diabetes",
author = "G. Derosa and A. D'Angelo and Ragonesi, {P. D.} and L. Ciccarelli and Piccinni, {M. N.} and F. Pricolo and Salvadeo, {S. A T} and L. Montagna and A. Gravina and I. Ferrari and S. Paniga and Cicero, {A. F G}",
year = "2007",
month = "2",
doi = "10.1111/j.1445-5994.2007.01238.x",
language = "English",
volume = "37",
pages = "79--86",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin

AU - Derosa, G.

AU - D'Angelo, A.

AU - Ragonesi, P. D.

AU - Ciccarelli, L.

AU - Piccinni, M. N.

AU - Pricolo, F.

AU - Salvadeo, S. A T

AU - Montagna, L.

AU - Gravina, A.

AU - Ferrari, I.

AU - Paniga, S.

AU - Cicero, A. F G

PY - 2007/2

Y1 - 2007/2

N2 - Background: Metformin is considered the gold standard for type 2 diabetes treatment as monotherapy and in combination with sulphonylureas and insulin, whereas the combination of metformin with thiazolidinediones is relatively less studied. The aim of the present study was to assess the differential effect on glycaemic metabolism and lipid variables of the combination of metformin plus pioglitazone or metformin plus rosiglitazone in diabetic patients with metabolic syndrome. Methods: All patients began metformin and were randomized to receive pioglitazone or rosiglitazone for 12 months. We assessed body mass index, glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, postprandial plasma insulin, homeostasis model assessment index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B. Results: Significant decreases in glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, and postprandial plasma insulin were seen after 9 and 12 months in both groups. Homeostasis model assessment index improved at 12 months in both groups. Significant total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B improvement was observed in pioglitazone group after 12 months, but not in the rosiglitazone group. These variations were significant between groups. Conclusion: The combination of metformin plus thiazolidinediones was able to improve glycaemic control compared with previous therapy. Pioglitazone was associated with a significant improvement in lipid and lipoprotein variables.

AB - Background: Metformin is considered the gold standard for type 2 diabetes treatment as monotherapy and in combination with sulphonylureas and insulin, whereas the combination of metformin with thiazolidinediones is relatively less studied. The aim of the present study was to assess the differential effect on glycaemic metabolism and lipid variables of the combination of metformin plus pioglitazone or metformin plus rosiglitazone in diabetic patients with metabolic syndrome. Methods: All patients began metformin and were randomized to receive pioglitazone or rosiglitazone for 12 months. We assessed body mass index, glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, postprandial plasma insulin, homeostasis model assessment index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B. Results: Significant decreases in glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, and postprandial plasma insulin were seen after 9 and 12 months in both groups. Homeostasis model assessment index improved at 12 months in both groups. Significant total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B improvement was observed in pioglitazone group after 12 months, but not in the rosiglitazone group. These variations were significant between groups. Conclusion: The combination of metformin plus thiazolidinediones was able to improve glycaemic control compared with previous therapy. Pioglitazone was associated with a significant improvement in lipid and lipoprotein variables.

KW - Lipid

KW - Metabolic syndrome

KW - Thiazolidinedione

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=33846092585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846092585&partnerID=8YFLogxK

U2 - 10.1111/j.1445-5994.2007.01238.x

DO - 10.1111/j.1445-5994.2007.01238.x

M3 - Article

C2 - 17229249

AN - SCOPUS:33846092585

VL - 37

SP - 79

EP - 86

JO - Internal Medicine Journal

JF - Internal Medicine Journal

SN - 1444-0903

IS - 2

ER -